반응식
[N:1]1([CH2:6][CH2:7][CH2:8][NH2:9])[CH:5]=[CH:4][N:3]=[CH:2]1.[CH2:10]([O:12][C:13]([C:15]1[C:16](=[O:38])[C:17]2[CH:22]=[N:21][C:20](S(C)(=O)=O)=[N:19][C:18]=2[N:27]([C:29]2[CH:30]=[C:31]3[C:35](=[CH:36][CH:37]=2)[CH2:34][CH2:33][CH2:32]3)[CH:28]=1)=[O:14])[CH3:11]>>[CH2:10]([O:12][C:13]([C:15]1[C:16](=[O:38])[C:17]2[CH:22]=[N:21][C:20]([NH:9][CH2:8][CH2:7][CH2:6][N:1]3[CH:5]=[CH:4][N:3]=[CH:2]3)=[N:19][C:18]=2[N:27]([C:29]2[CH:30]=[C:31]3[C:35](=[CH:36][CH:37]=2)[CH2:34][CH2:33][CH2:32]3)[CH:28]=1)=[O:14])[CH3:11]참가 물질
실험 절차
Using the procedure outlined in Example 1(Step F) the title compound was prepared from 3-imidazol-1-yl-propylamine (4.4 μL, 0.036 mmol) and 8-indan-5-yl-2-methanesulfonyl-5-oxo-5,8-dihydro-pyrido[2,3-d]pyrimidine-6-carboxylic acid ethyl ester (from Example 1(Step E), 15 mg, 0.036 mmol). 19.2 mg of 2-(3-imidazol-1-yl-propylamino)-8-indan-5-yl-5-oxo-5,8-dihydro-pyrido[2,3-d]pyrimidine-6-carboxylic acid ethyl ester was obtained as a white solid. 1H NMR (300 MHz, CDCl3) δ (ppm): 9.22 (s, 1H), 8.45 (s, 1H), 7.50 (br, 1H), 7.32 (d, 1H), 7.22 (s, 1H), 7.15 (d, 1H), 7.03 (br, 1H), 6.78 (br, 1H), 6.10 (br, 1H), 4.36 (q, 2H), 3.75 (m, 2H), 3.10 (m, 2H), 2.97 (m, 4H), 2.14 (m, 2H), 1.92 (m, 2H), 1.40 (t, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C25H26N6O3: 459.21 (M+H). Found: 459.4.
출처 및 근거
- ORD 기록
- ord-09ed7dd69e214258a42cde07500db0dc
- 출처 데이터셋
- uspto-grants-2010_06
- 특허 번호
- US07728003B2
연결된 노트
불러오는 중…